AUPH · Aurinia Pharmaceuticals Inc. · Proposed Sales
$16.56
+0.42 (+2.60%)
At close · Nov 3
Return incl. dividend (before tax)
Play latest call
Q4 2025 earnings call transcript
Market Cap
$2.22B
Shares
134.00M
Volume · Nov 3
1.18M
Avg daily vol (3M)
922.18K
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Notices of intent to sell restricted or control shares, filed with the SEC on Form 144 by insiders and affiliates. A Form 144 signals a planned sale — it does not confirm the shares were actually sold.
| Filed | Seller | Relationship | Shares | Approx. Sale | Broker |
|---|---|---|---|---|---|
| 2026-06-05 | GREGORY KEENAN | Former Affiliate | 9,593 | 2026-06-05 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-06-04 | GREGORY KEENAN | Former Affiliate | 25,000 | 2026-06-04 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-06-02 | GREGORY KEENAN | Officer | 25,000 | 2026-06-02 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-05-11 | PETER GREENLEAF | Former Affiliate | 3,136,201 | 2026-05-11 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-05-11 | JOSEPH MILLER | Former Affiliate | 500,503 | 2026-05-11 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-05-11 | MATTHEW MAXWELL DONLEY | Former Affiliate | 717,688 | 2026-05-11 | Morgan Stanley Smith Barney LLC Executive Financial Services |
Showing 1–6 of 6 filings
Key facts
CIK
1600620
CUSIP
05156V102
13F (30d)
91 filings
79 filers
Visit website
Investor relations